AlphAIalphai — Financial news for AI agents
SEC EDGARMAY 291 min read$ALKS

Parisi Samuel Joseph sold $687K of ALKS

Parisi Samuel Joseph (VP, Finance (Interim PAO)) sold 16,217 shares of Alkermes plc. (ALKS) at $42.36 ($0.69M total) on 2026-05-29.

Original reporting
SEC EDGAR · Parisi Samuel Joseph
Published May 29, 2026, 10:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ALKS
Bearish
medium confidence
Mentioned
$ALKS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSBearishLow
01

Why it matters

The disclosure updates insider activity records; it may slightly influence short-term sentiment but does not introduce new company fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but this single sale is unlikely to drive a durable repricing without accompanying fundamental news.

03

What to watch

No 10b5-1 plan is cited, but the filing still lacks context (e.g., diversification, tax obligations, pre-scheduled personal events), limiting inference about future fundamentals.

Relevance 6/10Novelty 6/10Timing: Filed same day (2026-05-29) as the sale date, for immediate awareness.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Alkermes (ALKS).

Company-level read

Ticker impact

$ALKSBearishMedium confidence
Context

Alkermes (ALKS) is the issuer of an SEC Form 4 showing VP Finance Parisi Samuel Joseph sold 16,217 shares on 2026-05-29.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional insider selling or company-specific news.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan stated; however, insider sales are common and the article provides no new operating/clinical/financial information.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical read-across provided.

Regional

None indicated; US-listed issuer only.

Global

None indicated; no cross-border deal/regulatory action mentioned.

Counterpoint

What could challenge this read

The sale could be liquidity/tax-driven and not a bearish view, especially since insider transactions often occur for non-informational reasons.

Key entities

  • issuer
    Alkermes plc

    Subject company for the SEC Form 4 insider sale disclosed on 2026-05-29.

  • insider
    Parisi Samuel Joseph

    VP, Finance (Interim PAO) who sold 16,217 ALKS shares for ~$687k.

Read at source← All news

Related articles

JUL 30
$ALKSMed

Alkermes plc Q2 2026 Earnings Call Summary

Strategic Evolution and Operational Context Management characterized the current period as a major phase of growth, with the orexin platform evolving from a hypersomnolence focus to a broad neurocircuitry platform for ADHD and fatigue. Alixorexton is positioned as a leading asset, being the only orexin 2 receptor agonist to demonstrate efficacy and tolerability across both NT1 and NT2 in large Phase 2 studies.

yahoo.com6 min
JUL 28
$ALKSMedAI 8/10

Alkermes plc. (ALKS): Results of Operations and Financial Condition

Alkermes plc. (ALKS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alks-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2026 Financial Results — Second Quarter Revenues of $496.0 Million — — GAAP Net Income

SEC EDGAR 8-K6 min
JUL 25
$ALKSMed

Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy

Alkermes plc reported interim results from a long-term extension study of alixorexton in adults with narcolepsy type 1 and type 2. At week 24, alixorexton showed sustained improvements on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale, with mean MWT sleep latency about 29 minutes (NT1) and 18 minutes (NT2) and mean ESS about 7.5 (NT1) and 8.9 (NT2). No serious treatment-emergent adverse events were reported.

sleepreviewmag.com5 min
JUL 23
$ALKSMed

First MS Mobility Drug Gets Green Light From NHS England

NHS England said it will make fampridine (Fampyra), a pill for adults with multiple sclerosis-related walking impairment, routinely available on the NHS after a Clinical Priorities Advisory Group review. NHSE cited trials showing improved walking speed in 43% of patients and about a 25% speed increase, with ~5,000 eligible patients in England in year one. The decision follows a 2022 NICE cost-effectiveness refusal and the expiry of the Fampyra brand patent.

medscape.com4 min